How Repeated Hexarelin Dosing Affects Growth Hormone Release Over Time
Repeated hexarelin doses maintain GH-releasing ability but show some desensitization, while continuous infusion leads to marked attenuation of GH response.
Quick Facts
What This Study Found
Pulsatile hexarelin dosing maintained GH-releasing efficacy with modest desensitization, while continuous infusion caused marked attenuation of GH response, supporting intermittent dosing strategies.
Key Numbers
How They Did This
In vivo rat study comparing IV, subcutaneous, and oral repeated dosing versus continuous IV infusion of hexarelin, with serial GH measurements to quantify response patterns.
Why This Research Matters
This study provides direct evidence for why GHRP dosing protocols emphasize pulsatile rather than continuous administration. The body's GH secretagogue receptors desensitize with continuous stimulation, meaning timing and dosing frequency are critical for maintaining therapeutic benefit.
The Bigger Picture
The desensitization pattern observed here mirrors what's seen clinically with many peptide hormones and helps explain GHRP dosing recommendations. The principle that pulsatile stimulation is superior to continuous exposure is fundamental to GH secretagogue therapy and echoes the body's own pulsatile GH release pattern.
What This Study Doesn't Tell Us
Rat study — desensitization kinetics may differ in humans. Short-term study — long-term desensitization patterns not characterized. Only hexarelin tested — other GHRPs may show different desensitization profiles.
Questions This Raises
- ?What is the optimal dosing interval to minimize hexarelin desensitization?
- ?Does desensitization fully reverse after a washout period?
- ?Do different GHRPs (ipamorelin, GHRP-2) show similar desensitization patterns?
Trust & Context
- Key Stat:
- Pulsatile > continuous Repeated discrete hexarelin doses maintained GH release, while continuous infusion led to marked desensitization
- Evidence Grade:
- Well-designed comparative animal study published in a respected endocrinology journal. Directly addresses clinically relevant dosing questions.
- Study Age:
- Published in 1998, this study established key principles about GHRP desensitization that continue to inform clinical dosing recommendations.
- Original Title:
- Effects of repeated doses and continuous infusions of the growth hormone-releasing peptide hexarelin in conscious male rats.
- Published In:
- The Journal of endocrinology, 158(3), 367-75 (1998)
- Authors:
- Conley, L K, Gaillard, R C, Giustina, A(3), Brogan, R S, Wehrenberg, W B
- Database ID:
- RPEP-00457
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
Why does continuous GHRP use stop working as well?
The GH secretagogue receptors in the brain and pituitary become desensitized with constant stimulation — they essentially turn down their sensitivity. Pulsatile dosing allows receptors to recover between doses, maintaining effectiveness.
What does this mean for people using GH-releasing peptides?
It supports the common practice of dosing GHRPs 2-3 times daily rather than continuously, and may also support cycling protocols with rest periods to prevent desensitization.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00457APA
Conley, L K; Gaillard, R C; Giustina, A; Brogan, R S; Wehrenberg, W B. (1998). Effects of repeated doses and continuous infusions of the growth hormone-releasing peptide hexarelin in conscious male rats.. The Journal of endocrinology, 158(3), 367-75.
MLA
Conley, L K, et al. "Effects of repeated doses and continuous infusions of the growth hormone-releasing peptide hexarelin in conscious male rats.." The Journal of endocrinology, 1998.
RethinkPeptides
RethinkPeptides Research Database. "Effects of repeated doses and continuous infusions of the gr..." RPEP-00457. Retrieved from https://rethinkpeptides.com/research/conley-1998-effects-of-repeated-doses
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.